Table 1.
Patient characteristics.
| N (Total = 92) | % | |
|---|---|---|
| Sex (f/m) | 31/61 | 34/66 |
| Diagnosis (malignant/non-malignant) | 69/23 | 75/25 |
| Age | ||
| ≤18 [Median (range)], years | 61 [7.7 (0.5–18.0)] | 66 |
| >18 [Median (range)], years | 31 [42.4 (18.4–65.6)] | 34 |
| Donor | ||
| Matched sibling donor | 21 | 23 |
| Matched unrelated donor | 56 | 61 |
| Mismatched unrelated donor | 1 | 1 |
| Haploidentical | 14 | 15 |
| Transplant source | ||
| Bone marrow | 41 | 45 |
| Peripheral blood stem cells | 49 | 53 |
| Umbilical cord blood | 2 | 2 |
| Conditioning | ||
| Total body irradiation based | 22 | 24 |
| Treosulfan based | 26 | 28 |
| Busulfan based | 21 | 23 |
| Fludarabine based | 21 | 23 |
| Others | 2 | 2 |
| Serotherapy | ||
| None | 29 | 32 |
| Anti-Thymocyte globulin (ATG) | 42 | 46 |
| Campath | 17 | 17 |
| Others | 4 | 4 |
| GvHD prophylaxis | ||
| None | 10 | 11 |
| Cyclosporin A (CSA) | 12 | 13 |
| CSA+methotrexate | 32 | 35 |
| CSA+mycophenolate mofetil (MMF) | 13 | 14 |
| Sirolimus+Tacrolimus | 5 | 5 |
| MMF+Tacrolimus | 5 | 5 |
| Others | 15 | 16 |
| aGvHD severity prior to MSC | ||
| grade II | 3 | 3 |
| grade III | 34 | 37 |
| grade IV | 54 | 59 |
| Not specified | 1 | 1 |
| # aGvHD therapies prior to 1st MSC dose | ||
| 1 | 8 | 9 |
| 2 | 17 | 18 |
| 3 | 31 | 34 |
| 4 | 16 | 17 |
| 5 | 12 | 13 |
| 6 | 4 | 4 |
| ≥7 | 4 | 4 |
Patient characteristics are listed; note the over-representation of male patients, of pediatric patients, of patients with underlying malignant disease, severe or very severe aGvHD and heavily pre-treated aGvHD.